Edwards Lifesciences Corporation (EW) News
Track canonical SquawkNews coverage tagged to EW, Edwards Lifesciences Corporation. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 47 indexed stories across 17 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
EW - Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
EW - Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
EQUITY | Sep 02, 2026, 08:19 PM UTC
L
Edwards Lifesciences to present at Deutsche Bank Healthcare Summit
Edwards Lifesciences (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit Wednesday, Sept. 16, 2026. CEO Bernard Zovighian is scheduled to present at 10:00 a.m. ET, with CFO Doretta Mistras also participati
EQUITY | Sep 02, 2026, 08:15 PM UTC
L
Edwards Lifesciences corporate VP Donald E. Bobo retires
Donald E. Bobo, Jr. is set to retire as Edwards Lifesciences corporate VP, and a successor search is underway.
EQUITY | Aug 28, 2026, 08:26 PM UTC
L
Edwards Lifesciences CVP sold shares worth over $2.8M
Edwards Lifesciences CVP sold shares worth over $2.8M, according to TradingView News.
EQUITY | Aug 26, 2026, 10:52 PM UTC
L
MRK upgraded to Overweight; price target raised to $179
Hammerstone MarketTalk upgrades MRK to Overweight and lifts its $179 price target from $116, while EW is listed as the prior designation.
EQUITY | Aug 19, 2026, 08:24 PM UTC
H
BMY AZN - pre-mkt note: W hile BMY-AZN merger could make sense for BMY at right price, AZN investors may find it hard to swallow given upcom
BMY AZN - pre-mkt note: W hile BMY-AZN merger could make sense for BMY at right price, AZN investors may find it hard to swallow given upcoming LOEs and significant pipeline risk. Wells sees FTC and geopolitics as the gr
MNA | Aug 03, 2026, 02:54 PM UTC
H
NCLH Another deep cut, this time to Q4 guidance and commentary around Q127; stay EW @ BARC
NCLH Another deep cut, this time to Q4 guidance and commentary around Q127; stay EW @ BARC
EQUITY | Jul 31, 2026, 11:28 AM UTC
H
TDOC Stay EW rated after results as BetterHelp remains a challenge @ BARC
TDOC Stay EW rated after results as BetterHelp remains a challenge @ BARC
EARNINGS | Jul 30, 2026, 11:17 AM UTC
M
CHD CL DLTR EW HD NI PG lows
CHD CL DLTR EW HD NI PG lows
EQUITY | Jul 28, 2026, 07:12 PM UTC
H
Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: UBS upgraded Intuitive Surgical (I
EARNINGS | Jul 28, 2026, 01:35 PM UTC
L
EW assumed Buy W/ $110 PT @ UBS
EW assumed Buy W/ $110 PT @ UBS
EQUITY | Jul 28, 2026, 12:45 PM UTC
H
EW UBS upgraded Edwards Lifesciences to Buy from Neutral with a price target of $110, up from $90, after assuming coverage of the name. Edwa
EW UBS upgraded Edwards Lifesciences to Buy from Neutral with a price target of $110, up from $90, after assuming coverage of the name. Edwards Lifesciences is entering a new growth phase driven by continued TAVR adoptio
EQUITY | Jul 28, 2026, 12:14 PM UTC
L
EW Initiated Buy W/$110.00 PT at UBS
EW Initiated Buy W/$110.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
FBRX downgraded to EW from Overweight after ARGX M&A headlines @ BARC
FBRX downgraded to EW from Overweight after ARGX M&A headlines @ BARC
MNA | Jul 28, 2026, 11:42 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
EW u/g Buy @ UBS
EW u/g Buy @ UBS
EQUITY | Jul 28, 2026, 09:18 AM UTC
L
CASY EA EW ESS HON WST session lows
CASY EA EW ESS HON WST session lows
EQUITY | Jul 24, 2026, 04:09 PM UTC
H
Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says
Edwards Lifesciences Corp. (NYSE: EW ) stock rose Friday after the medical device maker reported second-quarter results that topped Wall Street estimates and raised the low end of its full-year revenue guidance. The comp
EARNINGS | Jul 24, 2026, 03:48 PM UTC
L
moves among today's upgrades DLR +10.5%, CLF +7.9%, EW +5.5%, PGR +2.0%, AMKR +1.7%, DOV +1.3% moves among today's positive initiations OBDC
moves among today's upgrades DLR +10.5%, CLF +7.9%, EW +5.5%, PGR +2.0%, AMKR +1.7%, DOV +1.3% moves among today's positive initiations OBDC +0.8%, MAMA +2.2%
EQUITY | Jul 24, 2026, 01:40 PM UTC
L
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Truist upgraded PayPal (PYPL) to H
EQUITY | Jul 24, 2026, 01:34 PM UTC
L
PAG downgraded to EW from Overweight saying shares likely range-bound @ MSCO
PAG downgraded to EW from Overweight saying shares likely range-bound @ MSCO
EQUITY | Jul 24, 2026, 01:20 PM UTC
L
EW Upgrade from Market Perform to Outperform W/$101.00 PT (from $87.00) at Leerink
EW Upgrade from Market Perform to Outperform W/$101.00 PT (from $87.00) at Leerink
EQUITY | Jul 24, 2026, 12:15 PM UTC
L
EW upgraded from Market Perform to Outperform W/ $101 PT (from $87) @ Leerink
EW upgraded from Market Perform to Outperform W/ $101 PT (from $87) @ Leerink
EQUITY | Jul 24, 2026, 12:00 PM UTC
L
EW Reiterate Outperform and $110 PT after delivered an upside surprise on Q2 sales and EPS of 2% and 4% @ RBC
EW Reiterate Outperform and $110 PT after delivered an upside surprise on Q2 sales and EPS of 2% and 4% @ RBC
EARNINGS | Jul 24, 2026, 11:57 AM UTC
H
American Express, Deckers Outdoor And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mixed this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects American Express Co. (NYSE: AXP ) to post quarterly earnings of $4.4
EARNINGS | Jul 24, 2026, 06:16 AM UTC
H
Closing Bell Movers: Intel up 4% on Q2 earnings beat
Mega-cap Tech weighed heavily on sentiment in Thursday's trading as elevated capex plans by Alphabet (GOOGL) and Tesla (TSLA) worried investors. Parent of Google fell 7% to trade at a 3-month lows, while Tesla shed 15%,
RATES | Jul 24, 2026, 12:02 AM UTC
H
among movers from the earnings calendar after the close gainers INTC +9.4%, JAKK +7.8%, WKC +7.1%, EW +6.8%, UVE +6.2%, ATRC +3.0%, SSNC +2.
among movers from the earnings calendar after the close gainers INTC +9.4%, JAKK +7.8%, WKC +7.1%, EW +6.8%, UVE +6.2%, ATRC +3.0%, SSNC +2.9%, KN +2.2%, KNSL +2.2%, DLR +2.1%, AMTB +2.0%, ENVA +1.9%, OVV +1.0%, ORC +0.8
EARNINGS | Jul 23, 2026, 08:38 PM UTC
L
ITNC +12.8%, THC +10.5%, JAKK +5.6%, WKC +4.4%, SAP +4.4%, EW +4.3%, ATRC +3%, RNG +3%, SAM +3.1% after results
ITNC +12.8%, THC +10.5%, JAKK +5.6%, WKC +4.4%, SAP +4.4%, EW +4.3%, ATRC +3%, RNG +3%, SAM +3.1% after results
EQUITY | Jul 23, 2026, 08:21 PM UTC
L
Edwards Lifesciences affirms FY26 EPS view of $2.95-$3.05, consensus $3.01
Narrows higher FY26...
EQUITY | Jul 23, 2026, 08:20 PM UTC
H
Edwards Lifesciences up 4% at $87.50 after Q2 earnings beat and guidance
Edwards Lifesciences up 4% at $87.50 after Q2 earnings beat and guidance
EARNINGS | Jul 23, 2026, 08:20 PM UTC
H
EW Edwards Lifesciences RESULTS: Q2, Q2 sales $1.741B vs. EST $1.700B, Q2 EPS $0.42, Q2 ADJ EPS $0.78 vs. EST $0.74, Edwards Lifesciences Ea
EW Edwards Lifesciences RESULTS: Q2, Q2 sales $1.741B vs. EST $1.700B, Q2 EPS $0.42, Q2 ADJ EPS $0.78 vs. EST $0.74, Edwards Lifesciences Earnings Notes:, Reaffirms 2026 ADJ EPS guidance of $2.95-$3.05, Expects 2026 sale
RATES | Jul 23, 2026, 08:19 PM UTC
L
EW Edwards Lifesciences outlook Q3 adjusted EPS USD 0.71-0.77
EW Edwards Lifesciences outlook Q3 adjusted EPS USD 0.71-0.77
EARNINGS | Jul 23, 2026, 08:17 PM UTC
L
Edwards Lifesciences reports Q2 EPS 78c, consensus 74c
Reports Q2 revenue...
EQUITY | Jul 23, 2026, 08:17 PM UTC
H
Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.60
Edwards Lifesciences (NYSE: EW ) affirms FY2026 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $3.01 analyst estimate. Raises FY2026 sales outlook from $6.500 billion-$6.900 billion to $6.600 billion-$6.900 billion
EARNINGS | Jul 23, 2026, 08:16 PM UTC
H
Edwards Lifesciences options imply 6.5% move in share price post-earnings
Pre-earnings options...
EQUITY | Jul 23, 2026, 07:20 PM UTC
L
Implied EPS movers for tonight: INTC +/-10.4%, FIX +/-15.5%, NEM +/-5.0%, DLR +/-3.7%, EW +/-7.3%, MXL +/-30.1%, HIG +/-5.2%, SAP +/-6.9%, V
Implied EPS movers for tonight: INTC +/-10.4%, FIX +/-15.5%, NEM +/-5.0%, DLR +/-3.7%, EW +/-7.3%, MXL +/-30.1%, HIG +/-5.2%, SAP +/-6.9%, VRSN +/-8.0%, DECK +/-8.8%, OVV +/-8.6%, SSNC +/-7.5%, KNSL +/-9.5%, REXR +/-8.3%
EARNINGS | Jul 23, 2026, 06:09 PM UTC
L
Near 200dma support PEN PVH AXP MCO ALGN AGO EVR JLL HAS VRSN QCOM BIRK BKR EW QSR NLY OLN AMZN TTWO
Near 200dma support PEN PVH AXP MCO ALGN AGO EVR JLL HAS VRSN QCOM BIRK BKR EW QSR NLY OLN AMZN TTWO
EQUITY | Jul 23, 2026, 05:24 PM UTC
H
EW Earnings after close: qtr EPS est $0.74 (high $0.76/low $0.73), 30-day avg EPS revision n/a% (0 analyst(s) revised up, 0 down), qtr revs
EW Earnings after close: qtr EPS est $0.74 (high $0.76/low $0.73), 30-day avg EPS revision n/a% (0 analyst(s) revised up, 0 down), qtr revs est $1.70B; FY EPS est $3.01, FY revs est $6.75B; short interest 1.99%; implied
EARNINGS | Jul 23, 2026, 04:30 PM UTC
H
MOH Maintain EW after mixed Q2 results with HIX Pressure Offsetting Medicare Upside, EPS Guidance Increased $0.25 @ WELLS
MOH Maintain EW after mixed Q2 results with HIX Pressure Offsetting Medicare Upside, EPS Guidance Increased $0.25 @ WELLS
EARNINGS | Jul 23, 2026, 12:07 PM UTC
L
Near 200dma support DUK AGNC TJX EW NI ALK MAA
Near 200dma support DUK AGNC TJX EW NI ALK MAA
EQUITY | Jul 21, 2026, 05:49 PM UTC
L
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
BSX DXCM EW GEHC GMED MDT SYK ZBH readthroughs from ABT JNJ ISRG results @ RBC
EQUITY | Jul 21, 2026, 12:24 PM UTC
L
PYPL upgraded to EW from UW (late yesterday) @ BARC
PYPL upgraded to EW from UW (late yesterday) @ BARC
EQUITY | Jul 17, 2026, 12:39 PM UTC
L
WCC upgraded to overweight and downgraded GWW to EW from Overweight on valuation in distributors @ Stephens
WCC upgraded to overweight and downgraded GWW to EW from Overweight on valuation in distributors @ Stephens
EQUITY | Jul 14, 2026, 12:42 PM UTC
H
Edwards Lifesciences price target raised to $110 from $101 at Citi
Citi raised the firm's price target on Edwards Lifesciences to $110 from $101 and keeps a Buy rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtec
EARNINGS | Jul 08, 2026, 10:12 AM UTC
L
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $100 From $93
() -- Edwards Lifesciences (EW) has an average rating of overweight and mean price target of $98.50, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research
EQUITY | Jul 06, 2026, 01:11 PM UTC
L
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Edwards Lifesciences Corporation Insiders Breach th
EQUITY | Jul 03, 2026, 04:34 PM UTC
L
BTIG Maintains Buy on Edwards Lifesciences, Raises Price Target to $110
BTIG analyst Marie Thibault maintains Edwards Lifesciences (NYSE: EW ) with a Buy and raises the price target from $100 to $110.
EQUITY | Jun 30, 2026, 11:56 AM UTC